Publication Information (EuropePMC) | |
Title | Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. |
PubMed ID | 32273609(Europe PMC) |
doi | 10.1038/s41591-020-0800-0 |
Publication Date | April 7, 2020 |
Journal | Nat Med |
Author(s) | Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, Ahola-Olli A, Kurki M, Karjalainen J, Palta P, FinnGen, Neale BM, Daly M, Salomaa V, Palotie A, Widén E, Ripatti S. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000332 (PRS_BC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Breast cancer | breast carcinoma | 6,390,808 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000332/ScoringFiles/PGS000332.txt.gz | |
PGS000329 (PRS_CHD) |
PGP000100 | Mars N et al. Nat Med (2020) |
Coronary heart disease | coronary artery disease | 6,423,165 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000329/ScoringFiles/PGS000329.txt.gz | |
PGS000331 (PRS_AF) |
PGP000100 | Mars N et al. Nat Med (2020) |
Atrial fibrillation | atrial fibrillation | 6,183,494 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000331/ScoringFiles/PGS000331.txt.gz | |
PGS000330 (PRS_T2D) |
PGP000100 | Mars N et al. Nat Med (2020) |
Type 2 diabetes (T2D) | type 2 diabetes mellitus | 6,437,380 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000330/ScoringFiles/PGS000330.txt.gz | |
PGS000333 (PRS_PC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Prostate cancer | prostate carcinoma | 6,606,785 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000900 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.866 | — | age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000899 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.75 | — | age, family history of breast cancer, current smoking, BMI, alcohol use disorder, years of hormone replacement therapy, having given birth to one or more children, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000898 | PGS000331 (PRS_AF) |
PSS000439| European Ancestry| 10,561 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident atrial fibrillation | — | C-index: 0.734 | — | CHARGE-AF calculator (age, height, weight, SBP, DBP, smoking status, blood-pressure-lowering medication, diabetes, heart failure and history of myocardial infarction), FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 5-year risk |
PPM000897 | PGS000330 (PRS_T2D) |
PSS000441| European Ancestry| 21,030 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident type 2 diabetes | — | C-index: 0.845 | — | age, sex, BMI, history of stroke or CHD, parental history of diabetes, SBP, DBP, HDL, triglycerides, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000896 | PGS000329 (PRS_CHD) |
PSS000440| European Ancestry| 20,165 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident coronary heart disease | — | C-index: 0.82 | — | ASCVD risk calculator(age, sex, total cholesterol, HDL, SBP, blood-pressure-lowering medication, diabetes and smoking status), FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000895 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.857 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000894 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.737 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000893 | PGS000331 (PRS_AF) |
PSS000439| European Ancestry| 10,561 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident atrial fibrillation | HR: 1.62 [1.54, 1.7] | C-index: 0.751 | — | age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 5-year risk |
PPM000892 | PGS000330 (PRS_T2D) |
PSS000441| European Ancestry| 21,030 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident type 2 diabetes | HR: 1.7 [1.63, 1.78] | C-index: 0.763 | — | age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000891 | PGS000329 (PRS_CHD) |
PSS000440| European Ancestry| 20,165 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident coronary heart disease | HR: 1.25 [1.18, 1.32] | C-index: 0.832 | — | age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000890 | PGS000333 (PRS_PC) |
PSS000446| European Ancestry| 59,126 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Prostate cancer (incident and prevalent cases) | HR: 1.83 [1.78, 1.9] | — | — | genotyping array/batch, 10 ancestry PCs | — |
PPM000889 | PGS000332 (PRS_BC) |
PSS000443| European Ancestry| 76,173 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Breast cancer (incident and prevalent cases) | HR: 1.64 [1.6, 1.69] | — | — | genotyping array/batch, 10 ancestry PCs | — |
PPM000888 | PGS000331 (PRS_AF) |
PSS000442| European Ancestry| 135,300 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Atrial fibrillation (incident and prevalent cases) | HR: 1.62 [1.59, 1.65] | — | — | genotyping array/batch, 10 ancestry PCs, stratified by sex | — |
PPM000887 | PGS000330 (PRS_T2D) |
PSS000448| European Ancestry| 135,300 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Type 2 diabetes (incident and prevalent cases) | HR: 1.74 [1.72, 1.77] | — | — | genotyping array/batch, 10 ancestry PCs, stratified by sex | — |
PPM000886 | PGS000329 (PRS_CHD) |
PSS000445| European Ancestry| 135,300 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Coronary heart disease (incident and prevalent cases) | HR: 1.31 [1.29, 1.33] | — | — | genotyping array/batch, 10 ancestry PCs, stratified by sex | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000439 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
47.3 % Male samples |
Mean (Age At Baseline) = 48.0 years | European (Finnish) |
— | FINRISK | FINRISK surveys from 1992, 1997, 2002 and 2007 |
PSS000440 | Coronary heart disease was defined as Myocardial infarction|Myocardial infarction, strict|Complications following myocardial infarction|Prior myocardial infactrion|Angina pectoris|Other coronary atherosclerosis|Coronary artery bypass graft**|Coronary angioplasty**. ICD9/10 codes are listed in Table S9. National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. | — | [ ,
47.3 % Male samples |
Mean (Age At Baseline) = 48.0 years | European (Finnish) |
— | FINRISK | FINRISK surveys from 1992, 1997, 2002 and 2007 |
PSS000441 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
47.3 % Male samples |
Mean (Age At Baseline) = 48.0 years | European (Finnish) |
— | FINRISK | FINRISK surveys from 1992, 1997, 2002 and 2007 |
PSS000442 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
43.7 % Male samples |
Mean (Age At Baseline) = 59.2 years Sd = 16.6 years |
European (Finnish) |
— | FinnGen | — |
PSS000443 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
PSS000444 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
PSS000445 | Coronary heart disease was defined as Myocardial infarction|Myocardial infarction, strict|Complications following myocardial infarction|Prior myocardial infactrion|Angina pectoris|Other coronary atherosclerosis|Coronary artery bypass graft**|Coronary angioplasty**. ICD9/10 codes are listed in Table S9. National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. | — | [ ,
43.7 % Male samples |
Mean (Age At Baseline) = 59.2 years Sd = 16.6 years |
European (Finnish) |
— | FinnGen | — |
PSS000446 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
PSS000447 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
PSS000448 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
43.7 % Male samples |
Mean (Age At Baseline) = 59.2 years Sd = 16.6 years |
European (Finnish) |
— | FinnGen | — |